4/2/2024 0 Comments Rapt therapeutics stock price![]() These returns cover a period from Januthrough December 6, 2021. Since 1988 it has more than doubled the S&P 500 with an average gain of +25.25% per year. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. ![]() and Morningstar, Inc.Ĭopyright 2022 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606Īt the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Forbes Media, LLC Investor's Business Daily, Inc. Each of the company logos represented herein are trademarks of Microsoft Corporation Dow Jones & Company Nasdaq, Inc. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. The company's drug candidate consists of FLX475 for the treatment of tumors and RPT193, a CCR4 antagonist for allergic inflammatory disease. ![]() It focuses on discovering, developing and commercializing oral small molecule therapies for oncology and inflammatory diseases. is a clinical stage immunology-based biopharmaceutical company. See all Medical - Biomedical and Genetics Peers Zacks News for RAPT More Premium Research Premium Research: Industry Analysis Top Peers
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |